FMC Corp vs Novavax Inc — how do they compare? FMC Corp trades at $10.48 (market cap $1.31B), while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: FMC Corp and Novavax Inc are close in size by market cap, and FMC Corp pays a 3.06% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| FMC | NVAX | |
|---|---|---|
Market Cap | $1.31B | $1.30B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $11.19 |
52-Week Low | $10.01 | $6.22 |
Enterprise Value | $5.11B | $879.40M |
Dividend Yield | 3.06% | — |
Signals from Pluang's Aura AI — not financial advice
FMC trades at $10.59, up 0.38% today, with a bearish technical signal from moving averages. The stock shows mixed earnings beats but faces severe profitability challenges, with a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent news highlights revenue declines and cost management efforts, including a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and competitive pressures in agricultural sciences. Upside exists if operational improvements and debt reduction stabilize finances, but high volatility and margin pressures pose significant risks to shareholder value.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Trailing returns across standard periods
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →